Sorafenib in advanced hepatocellular carcinoma.

By J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. Blanc, A. C. de Oliveira, A. Santoro, J. Raoul, Alejandro Forner1 , 2 and 14 more. New England Journal of Medicine, 2008

6,212 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, background): “showing survival benefits in patients receiving sorafenib – a multi-tyrosine kinase inhibitor - in advanced cases.(320,321) The results of these randomised controlled trials represented a”
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017, positive): “Despite many potential therapeutic targets, sorafenib and regorafenib, related multikinase inhibitors, are currently the only drug approved for advanced HCC management (Llovet et al., 2008).”
MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. (2011, background): “The recent discovery of the efficacy of sorafenib, a multikinase inhibitor, as a treatment for patients with advanced HCC, has represented a major breakthrough in the clinical management, although the survival benefit has been shown to be less than 3 month”